- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 40/34 - Peptides antigéniques
Détention brevets de la classe A61K 40/34
Brevets de cette classe: 22
Historique des publications depuis 10 ans
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
10
|
3
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| The Trustees of the University of Pennsylvania | 4396 |
3 |
| BioNTech SE | 766 |
2 |
| The Regents of the University of California | 20447 |
1 |
| Amgen Inc. | 4318 |
1 |
| Industrial Technology Research Institute | 5071 |
1 |
| University of Florida Research Foundation, Inc. | 4132 |
1 |
| Atara Biotherapeutics, Inc. | 65 |
1 |
| Baylor College of Medicine | 986 |
1 |
| BioNTech Cell & Gene Therapies GmbH | 58 |
1 |
| City of Hope | 1015 |
1 |
| The Council of the Queensland Institute of Medical Research | 163 |
1 |
| The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | 118 |
1 |
| Joslin Diabetes Center, Inc. | 118 |
1 |
| Juno Therapeutics, Inc. | 486 |
1 |
| STEMCELL Technologies Canada Inc. | 291 |
1 |
| Translate bio, Inc. | 415 |
1 |
| BioNTech US Inc. | 89 |
1 |
| Fred Hutchinson Cancer Center | 463 |
1 |
| Remedium bio, Inc. | 10 |
1 |
| Autres propriétaires | 0 |